Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Still a Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw strong trading volume on Thursday . 1,614 shares changed hands during mid-day trading, an increase of 114% from the previous session’s volume of 755 shares.The stock last traded at $79.86 and had previously closed at $79.80.

Analysts Set New Price Targets

ZLDPF has been the topic of a number of research analyst reports. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Six research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Stock Performance

The company has a 50 day moving average price of $76.67 and a 200 day moving average price of $67.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 5.75 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The firm had revenue of $7.76 million during the quarter, compared to the consensus estimate of $4.54 million. Equities research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.